Whether coordinating a cell or gene therapy clinical trial or product launch, even the best-planned efforts can be derailed without a clear strategy for facilitating access to the therapy and supporting patients through the treatment journey.
The goal is to create a nimble, data-driven infrastructure that can connect the therapy to the customer base more effectively, helping to speed therapy onboarding for patients while improving visibility.
Pharma manufacturers must now understand how to navigate influence points within the healthcare ecosystem and support patients through the navigation of access, reimbursement, and affordability barriers.
It’s a long-standing perception that pharma overspends during launch, but we can now understand and validate this notion with data. Reasons and cost types were two major sets of drivers for why overspending consistently happened.
Whether you are an emerging company launching your first product or an established company expanding your portfolio, a number of parallel initiatives must be developed and executed to help your therapy get into the limelight.